?AIM: To analyze the effects on binocular vision after wearing Ortho K ( OK ) contact lens for myopic anisometropia.?METHODS:A total of 40 cases of myopic anisometropia corrected by Ortho K contact lens were collected. The average age of participants was 11. 32 ± 2. 56y. The refractive error varied from -1. 25D to -5. 75D, on average-3. 18±1. 12D. The amount of myopic anisometropia was-4. 64±1. 52D. All the cases were followed-up for 3mo. The uncorrected visual acuity ( UCVA ) , best corrected visual acuity ( BCVA ) , refraction and binocular vision were checked pre-wearing Ortho K contact lens, and 3mo post wearing respectively.?RESULTS:The mean UCVA was 4. 0±0. 2, and BCVA was 4. 96±0. 2, the amount of myopic anisometropia was -4. 64 ±1. 52D pre-wearing OK contact lens. The mean UCVA was 4. 97 ± 0. 07, and BCVA was 4. 99 ± 0. 1, the amount of myopic anisometropia was 0. 23 ± 0. 12D, at post wearing OK lens 3 months respectively. The UCVA, BCVA, the amount of myopic anisometropia at post correction was significantly difference with pre-correction (P<0. 05). Before correction, 36 cases got simultaneous binocular visions, 21 cases got combined visions, 13 cases got long distance stereopsis visions. Simultaneous binocular visions existed in 40 cases, combined visions existed in 36 cases, long distance stereopsis visions existed in 23 cases post correction 3mo. Compared with pre-correction, the difference was significantly. Before correction, 14 cases had macular fovea stereo vision. Abnormal stereo vision existed in 26 cases, including 13 cases with macula stereo <br> vision, 7 cases with peripheral stereo vision, and 6 cases with stereo vision blind. Macular fovea stereo vision was found in 27 cases, Abnormal stereo vision existed in 13 cases, including 7 cases with macula stereo vision, 3 cases with peripheral stereo vision, and 3 cases with stereo vision blind after wearing Ortho K contact lens 3mo.?CONCLUSION:Most myopic anisometropia patients can improve their visual acuity, reduce the refractive difference, and increase combined and stereopsis vision after wearing Ortho K contact lens 3mo.

AIM: To evaluate the pharmacokinetics of cyclosporine A(CyA)-loaded chitosan(CS) nanoparticles in rabbits after intravitreal injection. METHODS: Experimental study on pharmacokinetics of sustained release drug in vitreous. Twenty rabbits were intravitreally injected CyA-loaded CS nanoparticles. Liquid vitreous was aspirated at the time of 1 day, 2,3,5,7,9,11,14,21,28 days postoperatively for determination of CyA concentration by high-performance liquid chromatography. RESULTS: 81% of CyA was released in vitro from CyA-loaded CS nanoparticles after 14 days. The level of CyA ranged from 448.5ng/mL to 1237.7ng/mL during 28 days in vitreous cavities. CONCLUSION: Intravitreal injection of CyA-loaded CS nanoparticles leads to a sustained release of CyA with a high bioavailability. CS nanoparticles is a potentially promising delivery system for the posterior segment diseases.

Objective To observe the character of cyclosporin a-loaded chitosan nanoparticles[CS (CsA)-NP],and study the inhibitive effect of CS(CsA)-NP in rabbit's conjunctival fibroblasts(RCFs) proliferation in vitro.Methods The rabbit's conjunctival fibroblasts were divided into four groups;CS (CsA)-NP,original CsA,blank chitosan nanoparticle(CS-NP) and the control group.Different concentrations of drugs were test.The incubation time of drug was 24～72 hours.The cells growth conditions were observed with light microscope and the inhibition of the drugs to the RCFs were determined with the method of methyl thiazolyl tetrazolium(MTT) colorimetric assay.Results CS(CsA)-NP,original CsA and CSNP inhibited RCFs proliferation in experimental groups in comparison with that in the control group in a dose-dependent and time- dependent manner.The inhibitive effect of CS(CsA) -NP was more effective than in original CsA and CS-NP(P0.01).Conclusion CS(CsA)-NP can inhibit the proliferation of RCFs and can be be proposed as a potential controlled and targeted ophthalmic delivery system.

目的 评价环孢素A(CsA)壳聚糖纳米微粒抑制增生性玻璃体视网膜病变(PVR)的有效性和安全性.方法 20只健康中华大耳白兔制作的PVR动物模型随机分为4组:A组玻璃体腔内注入0.1 mL平衡液,B组玻璃体腔内注入0.1 mL壳聚糖溶液(含壳聚糖2 mg),C组玻璃体腔内注入0.1 mL CsA溶液(含CsA 0.1 mg),D组玻璃体腔内注入0.1 mL CsA壳聚糖纳米粒(含CsA 0.1 mg).以检眼镜、电生理、光镜和电镜观察视网膜变化情况.结果 玻璃体腔注药2周及4周后D组PVR等级均明显较A、B、C三组轻,组间差异具有统计学意义(P＜0.05);而A组与B组、B组与C组之间比较差异无统计学意义(P＞0.05).D组注药前与注药后4周暗适应闪光ERG b波振幅的差异无统计学意义(P＞0.05);D组注药后视网膜组织病理及超微结构未发现明显异常.结论 一次性兔眼玻璃体腔注入GsA壳聚糖纳米微粒(含CsA 0.1 mg)能明显抑制或延缓PVR的发生,并具有生物相容性及安全性。

Objective To study the effect of wavefront analyzer on refractive measurement of hyperopic and amblyopic children.Methods This is a prospective clinical study. 1% atroprin was applied to 102 eyes of 51 children.The children were examined with retinoscopy and wavefront analyzer respectively three days later.Results The results in sphere, astigmatism and axis measured with the wavefrontmefer were(+2.11±1.70)D,(+1.44±1.07)D, 78.82±35.15, and the results measured with retinoscopy were(+2.12±1.63)D, (+2.29±1.93)D, 75.41±38.45 respectively. The aberrations increased with the increasing of SE. BCVA was correlated with RMS2, RMSg. High order aberrations in low power of amblyopia were lower than those in middle power of amblyopia. With the increasing of astigmatism power, the aberrations especially trefoil, spherical, coma were larger. The difference between trefoil and vertical-coma was significant. Conclusion Allegretto wavefront analyzer can correctly evaluate refractive degree in children with hypermetropia and could be used as an object measure. At the same time, the analyzer of high order aberration is useful in investigating the cause of amblyopia.